General Biotechnology

Pharma procurement teams don’t buy “a drug.” They buy a system—and the real price shows up long after the invoice is paid.
That’s the uncomfortable truth behind a Total Cost of Ownership (TCO) model for drug procurement—an approach that forces decision…

Pharma doesn’t just “win” patents anymore—it extends them.
Drug patent term extensions—often framed as a technical fix for regulatory delays—have quietly become one of the most powerful levers in modern Big Pharma economics. And the numbers are hard to…

Generic drugmakers don’t “wait their turn.” They litigate their way to it.
For years, the public narrative around Hatch-Waxman has been simple: generic companies file an Abbreviated New Drug Application (ANDA), brand companies sue, and eventually the…

Drug patent cliffs don’t just threaten revenue—they reshape procurement. Here’s how to win before the exclusivity window closes.
If you’re selling branded medicines, you already know the calendar: patent loss of exclusivity (LOE) is rarely a surprise, …

Small Molecules vs. Biologics: The “Same” Patent Fight—But a Completely Different Playbook for Generics vs. Biosimilars
Most people treat drug patent strategy like a single sport: find the weak link, challenge the claims, and win the market. But when y…

Biopharma’s next growth cycle won’t be won in the lab—it’ll be won in the tender room.
If you’re a commercial vendor selling into EU healthcare systems, you already know the pattern: as patents approach loss of exclusivity, payers tighten scrutiny, f…

Drug patent expiry dates aren’t just legal milestones—they’re commercial calendars. And most teams treat them like a compliance checkbox instead of a revenue engine.
Here’s the agitation: if you’re waiting until a patent is “about to expire” to build y…

The smarter monopoly isn’t a patent. It’s orphan exclusivity.
If you want to understand why drug prices stay sticky—even after patents expire—look past the headline-grabbing “patent cliff” and into a quieter mechanism: orphan drug exclusivity. It’s d…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end”—they cliff. And when loss of exclusivity (LOE) hits, the market doesn’t politely wait for your pipeline to catc…

Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry narrative has been simple: once a patent expires, generics arrive, prices fall, and the market resets. But the real story—especially in branded pharmaceuti…